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Abstract
We present a case of man with portal vein thrombosis associated with complex inherited thrombophilia. 
The paper emphasises diagnostic and therapeutic difficulties in patients with visceral vein thrombosis. 
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Case study
A 42-year-old male, previously healthy, active sports-
man, with no significant medical history, denying smok-
ing, alcohol consumption and use of other stimulants. 
First signs of the disease appeared in form of diffuse 
abdominal pain and nausea. Several days before the 
patient had done some repair works at home and sus-
tained a minor abdominal injury. Initially mild symptoms 
had become exacerbated on subsequent days. For that 
reason the patient reported to the Emergency Room of 
a local hospital. During a hospitalisation in the Internal 
Medicine Ward, a slight yellowing of body integument 
and tenderness to palpation of the abdomen were 
found, with no pathological resistance or peritoneal 
signs. Laboratory investigations revealed an increased 
neutrophil count (78%) in the blood smear, with normal 
count of leukocytes (10.5 K/µl), increased aminotrans-
ferase (ALT 132 U/L, AST 118 U/L), bilirubin (4.6 mg/dL), 
CRP (120 mg/L) and ESR (52 mm/h) levels; and in-
creased urobilinogen level and the presence of ketone 
bodies in general urinalysis. Blood and urine amylase 
levels were normal. HBV, HCV, and CMV infection 
were ruled out. Stool investigation for presence of 
parasite eggs and the Giardia intestinalis antigen were 
negative. Imaging diagnostics was applied: X-ray of the 
chest, ultrasound examination of the abdomen, gas-
troscopy and colonoscopy. Besides some enlargement 
of the spleen (15 cm in the bipolar dimension) and 
some fine cysts in the right kidney, the investigations 
revealed no pathologies. Empirical therapy was ap-
plied — analgesics, relaxants, proton pump inhibitors, 
antibiotics (metronidazole, amoxicillin/clavulanic acid), 
anxiolytics — with no improvement. At that time, 
a CT of the abdomen and pelvis with a contrast medium 
was performed, that failed to provide any additional 
information. Description of the investigation stated: 
“large vessels of the abdomen appear normal“. With 
no significant improvement the patient was discharged 
to home, with a recommendation to report to a high-
er reference level centre in case of intensification of 
complaints. Two days later, because of deterioration of 
the patient’s general condition, he was admitted to the 
Teaching Department of Gastroenterology, with signs 
and symptoms of acute abdomen. Laboratory investi-
gations performed there revealed a significant leukocy-
tosis (34 K/µl), thrombocytaemia (994 K/µl), increased 
D-dimers and fibrinogen level (6.5 g/L). Emergency 
CT of the abdomen indicated presence of a significant 
volume of free fluid in the peritoneal cavity, thickening 
of small intestinal wall (up to 9 mm) with blurring of 
its internal outline and increased density of mesenteric 
fatty tissue (signs of venous stasis) and thrombosis of 
the portal vein, its branches and the superior mesen-
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Figure 3. AngioCT. Thrombosis of the portal vein and splenic 
vein confluence
Figure 1. AngioCT. Portal vein thrombosis
Figure 2. AngioCT. Thrombosis of the portal vein intrahepatic 
ramifications
teric vein (Fig. 1–3). The splenic vein was patent, with 
maintained outflow via the patent inferior mesenteric 
vein. Considering the patient’s poor general condition 
and increasing signs of enteral obstruction, the patient 
was qualified for laparotomy. The procedure revealed 
small intestinal wall necrosis over the distance of 70 cm 
starting 20 cm behind the ligament of Treitz. The re-
maining part of the small intestine also presented signs 
of ischaemia, but with no evident signs of necrosis. 
The necrotic section of the intestine was excised, with 
externalisation of a single-barrel ileostomy at the prox-
imal end. The distal section was closed completely. The 
abdominal cavity was left open for further stages of the 
surgical treatment. Resection of additional 100 cm of 
the intestine was necessary because of necrosis, and the 
total resected length of the small intestine was 170 cm. 
Pharmacotherapy involved low-molecular-weight hepa-
rin at therapeutic doses, adjusted for body weight. The 
surgical treatment was complicated by septic infection of 
the abdominal cavity and acute respiratory failure, with 
necessary transfer of the patient to the intensive care 
unit. Weakness, progressive body weight loss, dehydra-
tion, electrolyte balance disorders, hypoalbuminaemia, 
increased creatinine and urea levels, anaemia in course 
of short bowel syndrome were observed following 
the patient’s discharge. Parenteral nutrition had to be 
implemented. Persistent bilirubin, aminotransferase, 
GGTP, alkaline phosphatase, lipase and amylase levels 
observed in laboratory investigations were associated 
with hepatic injury being a result of past thrombosis of 
the portal system. Investigations for thrombophilia were 
carried out in order to determine a reason for visceral 
thrombosis. Diagnostic procedures revealed a complex 
haemostasis defect in form of the S protein deficiency, 
presence of the Leiden factor (heterozygote), polymor-
phism of the MTHFR gene and increased activity of the 
factor VIII (Tab. 1). Considering high risk thrombophilia, 
a long-term antithrombotic treatment was recommen-
ded. Coexistence of signs of the short bowel syndrome 
and hepatic injury limited possible application of oral 
antithrombotic agents. Therefore, LMW heparin was 
maintained, at a dose adjusted for body weight. 
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Table 1. Laboratory findings
Parameter Measured value Normal values
Red blood cells 5.8 million/µl 4.5–5.5 million/µl
Haemoglobin 13.2 g/dl 14–18 g/dl
White blood cells 8,500/µl 4,000–10,000/µl
Platelets 210,000/µl 140,000–440,000/µl
CRP 0.79 mg/l < 5.0 mg/l
Total cholesterol 142 mg/dl < 180 mg/dl
Triglycerides 111 mg/dl < 150 mg/dl
Homocysteine 12.7 µmol/l < 15 µmol/l
Albumin 4.3 g/dl 3.5–5.2 g/dl
ALT 212 U/l 0–45 U/l
AST 79 U/l 0–35 U/l
Total bilirubin 6 mg/dl 0.2–1.2 mg/dl
Alkaline phosphatase 194 U/l 30–120 U/l
Amylase 33 U/l 22–80 U/l
D-dimer 0.3 µg/ml < 0.5 µg/ml
APTT 32 s 25–37 s
Prothrombin index 83% 80–114%
INR 1.2 0.9–1.3
Fibrinogen 3.3 g/l 1.8–3.5 g/l
Antithrombin 92% 80–120%
Activated protein C 93% 70–140
Activated protein S free fraction 20% 75–130%
Protein S free fraction 47% 74–146%
Activated factor VIII 229% 70–150%
Lupus anticoagulant (LAC) LA1 screening test 35 s 30–40 s
aCI IgG < 2.0 GPL-E/ml
IgM < 2.0 MPL-E/ml
< 12 GPL-E/ml
< 12 MPL-E/ml
Anti-beta2GPI IgG < 2.0 Ru/ml
IgM < 2.0 Ru/ml
< 20 Ru/ml
Factor V Leiden G1691A G-A heterozygote
Prothrombin G20210A mutation G-G normal homozygote
MTHFR C667T polymorphism
MTHFR A1298C polymorphism
C-T heterozygote
A-C heterozygote
Discussion
Visceral vein thrombosis is responsible for 10–15% 
of cases of acute enteral ischaemia [1, 2]. Despite an 
unquestionable progress in diagnostics and therapy of 
visceral vein thrombosis observed recently, prognosis 
in that disease remains very serious, with a mortality 
rate reaching 30%. It is associated with deceitful onset 
of the disease, and development of symptoms within 
several days, which leads to delayed diagnosis reached 
when necrosis of the whole thickness of the intestinal 
wall had already developed. The delayed diagnosis is 
one of the principal reasons for poor prognosis. Direct 
complications of bowel necrosis (infection) and distant 
complications in form of the short bowel syndrome, 
present an additional burden to the unfavourable 
prognosis. A non-specific clinical presentation and 
lack of specific changes in laboratory investigations are 
a reason for the fact that a clear diagnosis is based only 
on results of imaging diagnostic procedures (CT, MRI). 
The following are mentioned as aetiology factors 
of visceral vein thrombosis: inflammation processes 
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(purulent) of the abdomen, hepatic disorders (cir-
rhosis), acute pancreatitis, tumours, injuries, surgical 
procedures and hypercoagulability (myeloproliferative 
diseases, thrombophilia). In many cases (up to 50%) the 
aetiology factor could not be established [1–3]. 
An antithrombotic therapy consistent with general 
principles is of crucial significance for treatment of 
visceral vein thrombosis [4, 5]. Surgical treatment 
is justified in case of presence of peritoneal signs, 
or in case of suspected bowel wall necrosis, before 
signs of peritoneal irritation develop. No major ran-
domised clinical trial regarding treatment of visceral 
vein thrombosis have been conducted so far. Current 
recommendations are experts’ opinions and are based 
on observation of small groups of patients. Initiation 
of heparin treatment is recommended in case of acute 
visceral vein thrombosis, and a continued medication 
with a vitamin K antagonist, lasting for not less than 
3 months [2]. In justified cases, in presence of a con-
stant prothrombotic factor (e.g. thrombophilia), the 
antithrombotic treatment should be long-term. In some 
cases also thrombolytic treatment is attempted, with 
administration of a fibrinolytic agent via the superior 
mesenteric artery, or by a direct cannulation of the 
portal vein. Unfortunately, the thrombolytic treatment 
is associated with a high incidence of haemorrhagic 
complications [6]. 
In the presented case the course of visceral vein 
thrombosis was (unfortunately) rather typical. Based 
on the medical history, the time from onset of first 
symptoms to the final diagnosis and introduction of an 
appropriate treatment was 4 weeks, including 2 weeks 
from the first patient’s contact with a medical centre. 
Late diagnosis has led to enteral wall necrosis with de-
velopment of septic complications, which significantly 
extended the time of hospitalisation and the convales-
cence period, and has also lead to necessary extensive 
resection of the small intestine and development of the 
short bowel syndrome. It may be speculated that an 
earlier diagnosis would allow avoiding severe compli-
cations of visceral vein thrombosis. The causal factor 
of the patient’s venous thrombosis was a complex 
defect of the clotting system — protein S deficiency, 
presence of the Leiden factor, MTHFR polymorphism 
and increased activity of the factor VIII. Undoubtedly, 
the S protein deficiency played a crucial role in that 
case. It is considered a very strong risk factor of ve-
nous thrombosis, often in a non-typical (organ-based) 
localisation. In case of the portal vein thrombosis with 
secondary hepatic injury, the assessment of meaning of 
the detected low protein S activity may be challenging. 
A reduced activity of natural anticoagulants (protein C, 
protein S, antithrombin), observed in those cases, may 
be a consequence of impairment of the hepatic synthe-
sizing function, thus being a result of thrombosis, and 
not its cause. The primary, congenital character of the 
protein S and other anticoagulants deficiency may be 
indicated by normal levels of plasma clotting factors 
(e.g. II, X), also being synthesised in the liver. In similar 
cases, the ratio of protein S and summed activity of 
the factor II and X multiplied by 0.5 may be applied: 
[protein S / (f. II + f. X) × 0.5]. If the ratio is < 0.7, it 
indicates a genetic deficiency of the anticoagulant or 
its neutralisation by antibodies [2]. In the presented 
case no signs of hepatic failure were observed, and the 
clotting time appeared normal, which could indicate 
a primary character of protein S deficiency. The Leiden 
factor, particularly its heterozygotic form, is a weak risk 
factor of thrombosis, and its presence is found also in 
some percentage of healthy population. Similarly, poly-
morphisms of the MTHFR gene, causing an increase 
in homocysteine level, contribute to increased risk 
of vascular thrombosis. However, their presence is 
considered a weak risk factor. The increased activity of 
the factor VIII elevates the risk of venous and arterial 
thrombosis [7, 8]. It should be noted, however, that 
the factor VIII is an acute phase protein and its activity 
rises transiently during the period of activation of an 
inflammation. In the discussed case the activity of the 
factor VIII was > 220%, with simultaneously low hsCRP 
level, which indicates its constitutive character. 
Antithrombotic treatment of patients with venous 
thrombosis of the portal system may pose some signi-
ficant difficulties. Hepatic injury secondary to the portal 
vein thrombosis often limits a possibility of application 
of oral antithrombotic agents (vitamin K antagonists, 
Rivaroxaban, Dabigatran). Absorption disorders being 
a consequence of the short bowel syndrome may lead 
to an unstable blood level of antithrombotic drugs. In 
the discussed case, a short preserved section of the 
small intestine, and a highly externalised stomy, have 
raised doubts about absorption of any oral drugs used 
by the patient. Will modern antithrombotic drugs 
offer any alternative in the therapy? Contrary to 
VKA preparations offering a possibility of monitoring 
of the antithrombotic effect by assessment of INR, 
modern drugs, including Rivaroxaban and Dabigatran 
have no standardised tests allowing assessment of 
their antithrombotic action. That limits their safe and 
effective use in case of a coexistent significant alimen-
tary tract absorption disorders or intensified hepatic 
dysfunctions. Additionally, Dabigatran is a prodrug, 
transformed into an active form in the liver. It should 
be also noted that in no clinical trial evaluating efficacy 
and safety of modern antithrombotic drugs in the ther-
apy of venous thromboembolic disease (RE-COVER, 
EINSTEIN) patients with organ-based thrombosis 
were randomised. 
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In the presented case it seems that the best solu-
tion was to carry on the antithrombotic therapy with 
low-molecular-weight heparin. 
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